Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/47395
Title: | Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C | Authors: | Fialho, Renata Pereira, Marco Harrison, Neil Rusted, Jennifer Whale, Richard |
Keywords: | Adult; Antiviral Agents; Coinfection; Depressive Disorder, Major; Drug Therapy, Combination; Female; HIV Infections; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin | Issue Date: | 2017 | Citation: | Fialho, R., Pereira, M., Harrison, N., Rusted, J., & Whale, R. (2017). Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C. Psychiatry Research, 253, 150-157. doi:10.1016/j.psychres.2017.03.049 | Serial title, monograph or event: | Psychiatry Research | Volume: | 253 | Abstract: | In this prospective study, we examined new-onset major depressive disorder (MDD) and the differential expression of depressive symptoms in a sample of 132 HCV mono-infected and 40 HIV/HCV co-infected patients initiating pegylated interferon-based treatment, including protease inhibitor therapy. The semi-structured clinical interview (SCID-I) was used to assess MDD. Severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale. Of the total sample, 60 patients (34.9%) developed SCID-I defined MDD during antiviral treatment. The proportion of HCV mono- and HIV/HCV patients developing MDD during treatment was not significantly different (37.9% vs. 25%; p=0.185). In both groups, there was a significant increase in HAMD total score from baseline to week 4, and a significant decrease between week 24 and 6 months post-treatment cessation. The greatest increase was observed in the symptoms of the neurovegetative syndrome. HCV mono-infected patients reported higher scores than co-infected patients, particularly impaired activity and somatic symptoms, but the differences were only significant at week 12. The finding that co-infected patients appear less vulnerable to the development of depressive symptoms during HCV treatment than HCV mono-infected patients warrants further exploration, including a thorough analysis of the biological and psychosocial factors associated with this emergence. | URI: | https://hdl.handle.net/10316/47395 | DOI: | 10.1016/j.psychres.2017.03.049 | Rights: | openAccess |
Appears in Collections: | FPCEUC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2017 Depression Co_Infection HIV_HCV.pdf | 759.84 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.